Raj Kumari

Name : Mrs.
RAJ KUMARI GC Client Name : DC - RPL DIAGNOSTIC CENTER - PUP1

Age/Gender : 78 Y 0 M 0 D /Female Registration Date : 15/Oct/2024 02:11PM
Patient ID : DDN110369 Collection Date : 15/Oct/2024 02:29PM
Barcode ID/Order ID : D3598472 / 10941825 Sample Receive Date : 15/Oct/2024 03:28PM
Referred By : Dr.RAKESH KUMAR AHLAWAT Report Status : Final Report
Sample Type : Fluoride Plasma F Report Date : 15/Oct/2024 05:09PM
BIOCHEMISTRY
Glucose Fasting_Camp
Test Name Result Unit Bio. Ref. Interval Method
Glucose - Fasting
Glucose - Fasting 90 mg/dL 70-99 Hexokinase
Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes
Reference : American Diabetes Association
Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes
Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c
This test has been performed at

TATA 1MG DEHRADUN
Address: 2nd Floor, Plot No. 1072, Ashirwad
Tower, Ballupur Road, Chakrata Rd, Sunder
Vihar, Dehradun, Uttarakhand 248001
* The parameters marked with an * are not- recognized by NABL.

Page 1 of 9
Name : Mrs.RAJ KUMARI GC Client Name : DC - RPL DIAGNOSTIC CENTER - PUP1
Sample Type : Serum Report Date : 15/Oct/2024 05:09PM
BIOCHEMISTRY
Lipid Profile_Camp
Lipid Profile
Cholesterol - Total 272 mg/dL Desirable <200, Enzymatic
Borderline High 200-239,
High >=240
Triglycerides 194 mg/dL Normal: < 150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200 - 499,
Very High >=500
Cholesterol - HDL 60 mg/dL Undesirable/high risk Elimination/catalase
<=40mg/dL
Desirable/low
risk>=60mg/dl
Cholesterol - LDL* 173 mg/dL Desirable:<100 Calculated
Above desirable:100-129
Borderline high :130-159
High : 160-189
Very high :>=190
Cholesterol- VLDL* 39 mg/dL <30 Calculated
Cholesterol : HDL Cholesterol* 4.5 Ratio Desirable : 3.0-4.0 Calculated
High Risk : >4
LDL : HDL Cholesterol* 2.88 Ratio Desirable : 2.0-2.5 Calculated
High risk : >3
Non HDL Cholesterol* 212 mg/dL Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220
Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial

TATA 1MG DEHRADUN

Page 2 of 9
BIOCHEMISTRY
Lipid Profile_Camp
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-
Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC
New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
Extreme Risk Gp Cat. A ≥50 ≥80 <50 (Optional ≤30) <80 (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months
•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.
Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

TATA 1MG DEHRADUN

Page 3 of 9
BIOCHEMISTRY
Lipid Profile_Camp

TATA 1MG DEHRADUN

Page 4 of 9
BIOCHEMISTRY
Urea
Urea 18.98 mg/dL 19.26 - 49.22 Calculated
Comment:
Elevated Blood Urea can occur with kidney disease, but it can also happen from high protein diet, increased protein
breakdown, certain medications, dehydration or burns, GI haemorrhage, cortisol and renal failure. Blood urea levels often
rise with aging as well.
Abnormally low levels of Blood Urea can be a sign of malnutrition, lack of protein in the diet, and liver disease.
Note:
Independently, blood urea may not reflect kidney function. For this reason, it is often interpreted in the context of other
measurements, such as creatinine, a breakdown product of the muscle, that is filtered by the kidneys.
In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by
multiplying by 2.14.

TATA 1MG DEHRADUN
Page 5 of 9
BIOCHEMISTRY
Creatinine
Creatinine 0.96 mg/dL 0.5-1.1 Alkaline picrate-kinetic
Comment:
Creatinine is a more specific and sensitive indicator of renal disease than Blood Urea Nitrogen.
Uses:
To diagnose renal insufficiency;

Adjusting dosage of renally excreted medications.
Monitoring renal transplant recipients.
Serum creatinine levels are a proxy for reduced skeletal muscle mass.
Serum creatinine measurement is used in estimating the Glomerular Filtration Rate (GFR) for people with Chronic Kidney
disease (CKD) and those with risk factors for CKD (Diabetes Mellitus, hypertension, cardiovascular disease, and family
history of kidney disease).
Increased In: Blockage in the urinary tract, Pre- and postrenal azotemia, Impaired kidney function, Loss of body fluid
(dehydration), Muscle diseases such as gigantism, acromegaly.
Decreased In: Pregnancy, certain drugs (e.g., cimetidine, trimethoprim), Myasthenia Gravis, Muscular dystrophy.

TATA 1MG DEHRADUN

Page 6 of 9
Immunology
Vitamon B12_Camp
Vitamin B12
Vitamin B12 > 2000 pg/ml 211-911 CLIA
Comment:
Vitamin B12 along with folate is essential for DNA synthesis and myelin formation.
Decreased levels a r e s e e n i n a n a e m i a , t e r m p r e g n a n c y , v e g e t a r i a n d i e t , i n t r i n s i c f a c t o r d e f i c i e n c y , p a r t i a l
gastrectomy/ileal damage, celiac disease, oral contraceptive use, parasitic infestation, pancreatic deficiency, treated
epilepsy, smoking, hemodialysis and advanced age.
Increased levels are seen in renal failure, hepatocelluar disorders, myeloproliferative disorders and at times with excess
supplementation of vitamins pills.

TATA 1MG DEHRADUN
Page 7 of 9
Sample Type : Urine Report Date : 15/Oct/2024 04:39PM
CLINICAL PATHOLOGY
Urine Routine & Microscopy

Colour* Pale Yellow Pale Yellow Manual
Appearance* Clear Clear Manual
Specific gravity 1.015 1.003 - 1.035 pKa change
pH 7.0 4.6 - 8.0 Double Indicator
Glucose Negative Negative GOD-POD
Protein Negative Negative Protein Error Principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Peroxidase
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Ehrlich
Leucocyte Esterase Negative Negative Pyrrole
Nitrite Negative Negative P-arsanilic acid
Pus cells* 2-4 /hpf 0-5 Microscopy
Red Blood Cells* Nil /hpf 0-2 Microscopy
Epithelial cells* 1-2 /hpf Few Microscopy
Casts* Nil Nil Microscopy
Crystals* Nil Nil Microscopy
Yeast* Nil Nil Microscopy
Bacteria* Nil Nil Microscopy
Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens
*** End Of Report ***

Conditions of Laboratory Testing & Reporting:

TATA 1MG DEHRADUN

Page 8 of 9
Sample Type : Urine Report Date : 15/Oct/2024 04:39PM
CLINICAL PATHOLOGY
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com
Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

TATA 1MG DEHRADUN

Page 9 of 9
Ensuring accuracy IN every single report
Following a 3-step review process:
Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor
Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >
Accurate Testing, Assured Quality: Diagnostics Precision
Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years
Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision
Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>
Get Second Opinion Order Medicines EXPLORE NOW >
Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618
*Clinical & Laboratory Standards Institute T&C Apply

Raj Kumari

Uploaded by

Copyright:

Available Formats

Raj Kumari

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Raj Kumari

Uploaded by

Copyright:

Available Formats

Name : Mrs.

RAJ KUMARI GC Client Name : DC - RPL DIAGNOSTIC CENTER - PUP1

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

Reference : American Diabetes Association

Plasma Glucose Goals For people with Diabetes

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

New treatment goals by Lipid Association of India (2020)

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

This test has been performed at

To diagnose renal insufficiency;

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

This test has been performed at

Urine Routine & Microscopy

*** End Of Report ***

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

This test has been performed at

* The parameters marked with an * are not- recognized by NABL.

Advanced systems & Experienced lab experts Each report undergoes

Have concerns regarding the report?

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Verified test procedures External assessments Trained phlebotomists

Claim FREE doctor consultation

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

*Clinical & Laboratory Standards Institute T&C Apply

You might also like

* End Of Report *